Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $6.75 Average PT from Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given an average rating of “Hold” by the eight brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $6.75.

Several research analysts have recently issued reports on INO shares. Citigroup reissued a “market outperform” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, November 4th. UBS Group restated an “overweight” rating on shares of Inovio Pharmaceuticals in a report on Friday, November 14th. Piper Sandler reaffirmed an “overweight” rating and set a $6.00 target price (up previously from $5.00) on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. HC Wainwright reiterated a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, December 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a report on Monday, December 29th.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ:INO opened at $1.61 on Friday. The stock has a market capitalization of $107.44 million, a price-to-earnings ratio of -0.62 and a beta of 1.62. Inovio Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $2.98. The company’s fifty day moving average is $1.87 and its two-hundred day moving average is $2.02.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.07. Sell-side analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. MCF Advisors LLC bought a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at approximately $26,000. SG Americas Securities LLC acquired a new stake in Inovio Pharmaceuticals in the third quarter worth about $27,000. Stephens Inc. AR bought a new stake in shares of Inovio Pharmaceuticals during the third quarter worth approximately $32,000. Focus Partners Wealth acquired a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at $33,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 5,894 shares during the last quarter. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.